| __timestamp | Insmed Incorporated | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 31073000 | 504755000 |
| Thursday, January 1, 2015 | 43216000 | 838526000 |
| Friday, January 1, 2016 | 50679000 | 1177697000 |
| Sunday, January 1, 2017 | 79171000 | 1320433000 |
| Monday, January 1, 2018 | 168218000 | 1556200000 |
| Tuesday, January 1, 2019 | 210796000 | 1834800000 |
| Wednesday, January 1, 2020 | 203613000 | 1346000000 |
| Friday, January 1, 2021 | 234273000 | 1824900000 |
| Saturday, January 1, 2022 | 265784000 | 2115900000 |
| Sunday, January 1, 2023 | 344501000 | 2631300000 |
| Monday, January 1, 2024 | 2954400000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, understanding the financial strategies of industry leaders is crucial. Over the past decade, Regeneron Pharmaceuticals, Inc. and Insmed Incorporated have demonstrated distinct approaches to managing Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Regeneron's SG&A costs surged by over 420%, peaking at approximately $2.63 billion in 2023. This reflects their aggressive expansion and investment in operational infrastructure. In contrast, Insmed's SG&A expenses grew by nearly 1,000%, reaching around $344 million in the same year, indicating a strategic scaling of their operations. This divergence highlights the varied financial strategies within the biotech sector, where Regeneron focuses on broadening its market reach, while Insmed emphasizes targeted growth. These insights provide a window into the financial health and strategic priorities of these two biotech giants.
Selling, General, and Administrative Costs: Johnson & Johnson vs Regeneron Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Insmed Incorporated
Breaking Down SG&A Expenses: Sanofi vs Regeneron Pharmaceuticals, Inc.
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs Regeneron Pharmaceuticals, Inc. Trends and Insights
R&D Spending Showdown: Regeneron Pharmaceuticals, Inc. vs Insmed Incorporated
Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Limited: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Genmab A/S
SG&A Efficiency Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Regeneron Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Insmed Incorporated
Insmed Incorporated or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?